Developed using Lunit’s cutting-edge deep learning technology, Lunit INSIGHT MMG accurately detects lesions suspicious of breast cancer in the form of diagnostic support tool. The AI solution generates (1) location information of detected lesions in the form of heatmaps and (2) abnormality scores reflecting the probability that the detected lesion is malignant. The solution is indicated to be directly involved in the primary interpretation process of radiologists.

Value Proposition

Increase (max. 18%) in breast cancer detection rate, decrease (max. 14%) in false positive rate
Improved accuracy for dense breasts, with 11% higher ROC AUC
Detection of early-stage invasive cancers

Training & Validation

Trained with a large-scale (>200,000 total cases, >50,000 cancer cases), high-quality (biopsy-proven cases) training set
Demonstrated to perform at a standalone accuracy of 96% in ROC AUC
Clinically validated to significantly improve the interpretive capabilities of radiologists up to 10%
Approved by Korea MFDS
Currently in preparation for regulatory approval in various markets worldwide, including FDA, CE

Medical Publications

Applying Data-driven Imaging Biomarker in Mammography for Breast Cancer Screening: Preliminary Study, Kim EK, Kim HE et al., Scientific Reports 2018
Changes in Cancer Detection and False-positive Recall in Mammography Using Artificial Intelligence: A Retrospective, Multireader Study, Kim HE, Kim HK, Han BK et al., The Lancet Digital Health 2020

**THIS PRODUCT IS NOT FDA 510(K) CLEARED, NOT FOR SALE IN THE U.S.*

Lunit INSIGHT MMG

Видавець: Lunit